Filing Flows › Allogene Therapeutics (ALLO) › Guidance history
Allogene Therapeutics (ALLO) guidance history: what it guided and what it reported
Allogene Therapeutics gave guidance in 2 earnings releases on file since Aug 12, 2026. Its releases raised guidance once and lowered it 0 times.
GAAP operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $225M (Aug 12, 2026) → reaffirmed $225M (Nov 5, 2026) | — | to be reported | — |
The latest quarter
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
Questions
Does Allogene Therapeutics beat its guidance?
Allogene Therapeutics gave guidance in 2 earnings releases on file since Aug 12, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Allogene Therapeutics raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since Aug 12, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.